KITE PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
Clinical Trials
64
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- Conditions
- Systemic Lupus ErythematosusLupus NephritisSystemic SclerosisIdiopathic Inflammatory Myopathy
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 52
- Registration Number
- NCT07038447
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Syndey, New South Wales, Australia
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 25
- Registration Number
- NCT06253663
- Locations
- 🇯🇵
Chiba University Hospital, Chiba, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
🇯🇵Hokkaido University Hospital, Hokkaido, Japan
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 39
- Registration Number
- NCT06079164
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Conditions
- Large B-cell LymphomaFollicular Lymphoma
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776160
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
CAR T-cell Therapy Monitoring: Study Suggests Reduced REMS May Improve Accessibility
A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility.